» Articles » PMID: 1847886

Nonenzymatic Glycosylation of HDL and Impaired HDL-receptor-mediated Cholesterol Efflux

Overview
Journal Diabetes
Specialty Endocrinology
Date 1991 Mar 1
PMID 1847886
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Previous studies have shown that nonenzymatic glycosylation of high-density lipoprotein (HDL) inhibits high-affinity binding to cultured cells and the candidate HDL-receptor protein. Because binding of HDL to its receptor is required for HDL-receptor-mediated cholesterol efflux from cells, we hypothesized that glycosylated HDL3 would have reduced ability to remove cholesterol from cells. HDL3 was glycosylated in vitro to achieve up to 40-50% reductions in free-lysine residues. Glycosylated HDL3 had a slightly greater ability than control HDL3 to sequester cholesterol directly from the plasma membrane, as predicted by changes in lipid composition. This process is independent of HDL-receptor binding and should not be influenced by reduced binding of HDL3. In contrast, efflux of intracellular cholesterol from cells, which is HDL-receptor dependent, was reduced 25-40%. The ability of glycosylated HDL3 to diminish cholesterol esterification was significantly reduced, indicating reduced net cholesterol efflux. Steady-state efflux of LDL-derived cholesterol was also markedly reduced. These findings suggest that nonenzymatically glycosylated HDL is functionally abnormal and might contribute to the accelerated development of atherosclerosis in patients with diabetes mellitus.

Citing Articles

Lipids at the Nexus between Cerebrovascular Disease and Vascular Dementia: The Impact of HDL-Cholesterol and Ceramides.

Sergi D, Zauli E, Tisato V, Secchiero P, Zauli G, Cervellati C Int J Mol Sci. 2023; 24(5).

PMID: 36901834 PMC: 10002119. DOI: 10.3390/ijms24054403.


High-Density Lipoprotein Alterations in Type 2 Diabetes and Obesity.

Denimal D, Monier S, Bouillet B, Verges B, Duvillard L Metabolites. 2023; 13(2).

PMID: 36837872 PMC: 9967905. DOI: 10.3390/metabo13020253.


Alterations of HDL's to piHDL's Proteome in Patients with Chronic Inflammatory Diseases, and HDL-Targeted Therapies.

Vyletelova V, Novakova M, Paskova L Pharmaceuticals (Basel). 2022; 15(10).

PMID: 36297390 PMC: 9611871. DOI: 10.3390/ph15101278.


HDL Composition, Heart Failure, and Its Comorbidities.

Diab A, Valenzuela Ripoll C, Guo Z, Javaheri A Front Cardiovasc Med. 2022; 9:846990.

PMID: 35350538 PMC: 8958020. DOI: 10.3389/fcvm.2022.846990.


High Density Lipoproteins and Diabetes.

Cochran B, Ong K, Manandhar B, Rye K Cells. 2021; 10(4).

PMID: 33918571 PMC: 8069617. DOI: 10.3390/cells10040850.